Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380793650> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4380793650 abstract "Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder with extremely high low-density lipoprotein cholesterol (LDL-C) levels that contributes to atherosclerotic cardiovascular disease and death, even in adolescent. Ongericimab, a monoclonal antibody against human proprotein convertase subtilisin/kexin type 9 (PCSK9), inhibits PCSK9-mediated degradation of LDL receptor (LDLR), and reduces LDL-C by 58.3-66.5% in Chinese patients with hyperlipidemia. Due to the high genetic heterogeneity of HoFH, the LDL-C lowering effect of Ongericimab remains elusive in Chinese population. This is the first study to assess the efficacy and safety of anti-PCSK9 antibody in Chinese patients with HoFH. Methods: This is a single arm, open-label phase 2 study. 31 patients (aged ≥12 years) with HoFH diagnosed by clinical or genetic criteria, on stable lipid-lowering therapies for ≥4 weeks, were enrolled to receive subcutaneous Ongericimab 450 mg every 4 weeks for 52 weeks. The primary endpoint was percentage change in LDL-C from baseline at week 12. Results: At the time of this interim analysis, 30 out of 31 patients completed 12 weeks treatment. All patients were on statins (77.4% on high intensity statin) and the mean (SD) baseline LDL-C was 8.6 (3.1) mmol/L. The least squares mean percentage change in LDL-C from baseline was -12.6% (95% CI: -19.7%, -5.6%; p=0.001) at week 12. Further analysis based on residual LDLR activity, the mean (SD) LDL-C change from baseline was -21.7 (28.0)% in 14 patients with defective LDLR (at least one defective allele) and -1.4 (9.6)% in 7 patients with negative LDLR (at least one negative allele), respectively (Figure 1). No serious side effects were reported. Conclusion: Ongericimab was well tolerated and significantly reduced LDL-C levels in Chinese patients with HoFH. Patients with defective LDLR demonstrated better response than those with negative LDLR." @default.
- W4380793650 created "2023-06-16" @default.
- W4380793650 creator A5005126432 @default.
- W4380793650 creator A5018254630 @default.
- W4380793650 creator A5019448133 @default.
- W4380793650 creator A5030689354 @default.
- W4380793650 creator A5034764782 @default.
- W4380793650 creator A5053339178 @default.
- W4380793650 creator A5058021944 @default.
- W4380793650 creator A5062637798 @default.
- W4380793650 creator A5066606190 @default.
- W4380793650 date "2022-11-08" @default.
- W4380793650 modified "2023-09-27" @default.
- W4380793650 title "Abstract 10921: Efficacy and Safety of Ongericimab in Chinese Patients With Homozygous Familial Hypercholesterolemia" @default.
- W4380793650 doi "https://doi.org/10.1161/circ.146.suppl_1.10921" @default.
- W4380793650 hasPublicationYear "2022" @default.
- W4380793650 type Work @default.
- W4380793650 citedByCount "0" @default.
- W4380793650 crossrefType "journal-article" @default.
- W4380793650 hasAuthorship W4380793650A5005126432 @default.
- W4380793650 hasAuthorship W4380793650A5018254630 @default.
- W4380793650 hasAuthorship W4380793650A5019448133 @default.
- W4380793650 hasAuthorship W4380793650A5030689354 @default.
- W4380793650 hasAuthorship W4380793650A5034764782 @default.
- W4380793650 hasAuthorship W4380793650A5053339178 @default.
- W4380793650 hasAuthorship W4380793650A5058021944 @default.
- W4380793650 hasAuthorship W4380793650A5062637798 @default.
- W4380793650 hasAuthorship W4380793650A5066606190 @default.
- W4380793650 hasConcept C126322002 @default.
- W4380793650 hasConcept C134018914 @default.
- W4380793650 hasConcept C203092338 @default.
- W4380793650 hasConcept C2776839432 @default.
- W4380793650 hasConcept C2777482532 @default.
- W4380793650 hasConcept C2778163477 @default.
- W4380793650 hasConcept C2779091943 @default.
- W4380793650 hasConcept C2779120738 @default.
- W4380793650 hasConcept C2780072125 @default.
- W4380793650 hasConcept C2780499067 @default.
- W4380793650 hasConcept C2780948078 @default.
- W4380793650 hasConcept C2908647359 @default.
- W4380793650 hasConcept C43554185 @default.
- W4380793650 hasConcept C535046627 @default.
- W4380793650 hasConcept C555293320 @default.
- W4380793650 hasConcept C61943457 @default.
- W4380793650 hasConcept C71924100 @default.
- W4380793650 hasConcept C90924648 @default.
- W4380793650 hasConcept C99454951 @default.
- W4380793650 hasConceptScore W4380793650C126322002 @default.
- W4380793650 hasConceptScore W4380793650C134018914 @default.
- W4380793650 hasConceptScore W4380793650C203092338 @default.
- W4380793650 hasConceptScore W4380793650C2776839432 @default.
- W4380793650 hasConceptScore W4380793650C2777482532 @default.
- W4380793650 hasConceptScore W4380793650C2778163477 @default.
- W4380793650 hasConceptScore W4380793650C2779091943 @default.
- W4380793650 hasConceptScore W4380793650C2779120738 @default.
- W4380793650 hasConceptScore W4380793650C2780072125 @default.
- W4380793650 hasConceptScore W4380793650C2780499067 @default.
- W4380793650 hasConceptScore W4380793650C2780948078 @default.
- W4380793650 hasConceptScore W4380793650C2908647359 @default.
- W4380793650 hasConceptScore W4380793650C43554185 @default.
- W4380793650 hasConceptScore W4380793650C535046627 @default.
- W4380793650 hasConceptScore W4380793650C555293320 @default.
- W4380793650 hasConceptScore W4380793650C61943457 @default.
- W4380793650 hasConceptScore W4380793650C71924100 @default.
- W4380793650 hasConceptScore W4380793650C90924648 @default.
- W4380793650 hasConceptScore W4380793650C99454951 @default.
- W4380793650 hasIssue "Suppl_1" @default.
- W4380793650 hasLocation W43807936501 @default.
- W4380793650 hasOpenAccess W4380793650 @default.
- W4380793650 hasPrimaryLocation W43807936501 @default.
- W4380793650 hasRelatedWork W1595175397 @default.
- W4380793650 hasRelatedWork W2053355529 @default.
- W4380793650 hasRelatedWork W2213977181 @default.
- W4380793650 hasRelatedWork W2285307429 @default.
- W4380793650 hasRelatedWork W2790951009 @default.
- W4380793650 hasRelatedWork W3014308787 @default.
- W4380793650 hasRelatedWork W3118524798 @default.
- W4380793650 hasRelatedWork W3204512944 @default.
- W4380793650 hasRelatedWork W4200571576 @default.
- W4380793650 hasRelatedWork W4293579014 @default.
- W4380793650 hasVolume "146" @default.
- W4380793650 isParatext "false" @default.
- W4380793650 isRetracted "false" @default.
- W4380793650 workType "article" @default.